ALLK - Allakos Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
39.20
-0.47 (-1.18%)
At close: 4:00PM EDT

39.20 0.00 (0.00%)
After hours: 5:22PM EDT

Stock chart is not supported by your current browser
Previous Close39.67
Open39.84
Bid37.50 x 1000
Ask46.00 x 1200
Day's Range38.49 - 40.12
52 Week Range26.00 - 65.48
Volume288,615
Avg. Volume424,471
Market Cap1.69B
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-2.19
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est69.67
Trade prices are not sourced from all markets
  • GlobeNewswire5 days ago

    Allakos Reports Fourth Quarter and Full Year 2018 Financial Results and 2018 Corporate Highlights

    REDWOOD CITY, Calif., March 14, 2019 -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases,.

  • State-backed VC vehicle managers aren't worried about dipping into tax credits – here's why
    American City Business Journals8 days ago

    State-backed VC vehicle managers aren't worried about dipping into tax credits – here's why

    Ohio Capital Fund LLC used $7 million in state tax credits to meet the fund of fund's February payments on its bonds, as portfolio companies show signs of success.

  • GlobeNewswire28 days ago

    Allakos Announces Positive Phase 1 Results with AK002 in Indolent Systemic Mastocytosis

    REDWOOD CITY, Calif., Feb. 19, 2019 -- Allakos Inc. (NASDAQ: ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases,.

  • Allakos Enters Oversold Territory
    Zackslast month

    Allakos Enters Oversold Territory

    Allakos Inc. (ALLK) has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

  • GlobeNewswirelast month

    Allakos Announces Positive Phase 2 Results for AK002 in Patients with Xolair Refractory Chronic Spontaneous Urticaria and Provides Additional Data from Chronic Urticaria Study Cohorts

    -- 55% (6/11) response rate by UCT in Xolair Refractory CSU patients ---- 49% reduction in UAS7 in Xolair Refractory CSU patients -- -- 77% (10/13) complete hive response by.

  • GlobeNewswirelast month

    Allakos to Host Investor Day on February 19 in New York City

    Allakos Inc. (ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced that it will host an Investor Day on February 19th starting at 12:00 pm ET in New York City. The event will feature an overview of the AK002 development program, including a presentation of the chronic urticaria and indolent systemic mastocytosis (ISM) clinical results to date by Dr. Marcus Maurer, M.D., Professor of Dermatology and Allergy at Charité University in Berlin, a noted expert in the field of urticaria, indolent systemic mastocytosis, and other allergic conditions.

  • GlobeNewswire2 months ago

    Allakos Announces Positive Phase 2 Results in Patients with Cholinergic Urticaria and Symptomatic Dermographism

    Allakos Inc. (ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced positive Phase 2 results from two additional chronic urticaria cohorts: patients with cholinergic urticaria and symptomatic dermographism (also referred to as dermatographic urticaria). Earlier this month, Allakos reported that 12 of 13 patients (92%) in the Xolair-naïve chronic spontaneous urticaria (CSU) cohort achieved a complete response with AK002. Top-line results for the remaining urticaria cohort, patients with chronic spontaneous urticaria who failed to respond to Xolair, are expected later in the first quarter of 2019.

  • GlobeNewswire2 months ago

    Allakos Announces Positive Phase 2 Results in a Cohort of Xolair-Naïve Chronic Spontaneous Urticaria Patients

    Allakos Inc. (ALLK), a biotechnology company developing AK002 for the treatment of eosinophil and mast cell related diseases, today announced positive top-line results for the Xolair-naïve chronic spontaneous urticaria (CSU) cohort from its Phase 2 study. The principle investigator is Dr. Marcus Maurer, MD, Professor of Dermatology and Allergy at Charité University in Berlin. The Xolair-naïve chronic spontaneous urticaria cohort enrolled 13 patients with uncontrolled urticaria despite treatment with H1 antihistamines at doses of up to 4 times the labeled dosage.

  • American City Business Journals2 months ago

    Here are the winners and losers from Bay Area's IPO class of 2018

    Most stocks from last year's class of Bay Area IPO companies ended the year in positive territory, with 23 of them closing 2018 above their IPO offering prices. Here's a look at all of them, as Wall Street volatility threatens the planned 2019 IPOs of a number of the most closely watched startups.

  • 5 Best-Performing IPOs of 2018
    Zacks3 months ago

    5 Best-Performing IPOs of 2018

    Strong economic fundamentals and increased foreign investment have led to such a high number of companies going public.

  • Barrons.com3 months ago

    Assessing the Performance of 2018’s Major IPOs

    Some 81% of the companies that went public in 2018 priced in or above their indicated range—the most in over a decade, according to Renaissance Capital, a manager of IPO exchange-traded funds. The 2018 class of initial public offerings has now returned minus 2.3% this year, versus the five-year average return of 20%. In total, 190 companies—almost 20% more than 2017 and the most since 2014—went public, Renaissance Capital says.

  • Allakos (ALLK) Catches Eye: Stock Jumps 6.5%
    Zacks3 months ago

    Allakos (ALLK) Catches Eye: Stock Jumps 6.5%

    Allakos (ALLK) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

  • Here's how much better insiders have profited from this year's IPO boom
    American City Business Journals4 months ago

    Here's how much better insiders have profited from this year's IPO boom

    If you bought one share at the IPO price of each of the Bay Area companies who went public this year, your portfolio would be up 37 percent on the year. But you would only have a 3 percent return if you bought all of those shares at their opening market price.

  • Has Allakos Inc (NASDAQ:ALLK) Got Enough Cash?
    Simply Wall St.4 months ago

    Has Allakos Inc (NASDAQ:ALLK) Got Enough Cash?

    Stocks with market capitalization between $2B and $10B, such as Allakos Inc (NASDAQ:ALLK) with a size of US$2.3b, do not attract as much attention from the investing community as do Read More...

  • Benzinga7 months ago

    Mixed Reviews For Allakos As Sell-Side Starts Coverage Of Biotech

    Allakos Inc (NASDAQ: ALLK ), a clinical-stage biotech company developing treatment for various eosinophil and mast-cell related diseases, offered 7.13 million shares in an IPO  at $18 per share. The Analysts ...